Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation

 

• Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.
• New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.
• Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally involved in the pathogenesis of MSA. The U.S. FDA granted Orphan Drug designation to emrusolmin for MSA in 2022.

https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Tevas-Emrusolmin-Granted-U-S--FDA-Fast-Track-Designation-for-Treatment-of-Multiple-System-Atrophy/default.aspx